Second Quarter 2024 Business Update August 8, 2024 © 2024 Scholar Rock, Inc. All rights reserved. 1 Forward-Looking Statements Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock Holding Corporation and Scholar Rock, Inc. (collectively, "Scholar Rock"), including without limitation, Scholar Rock's expectations regarding its strategy, its product candidate selection and development timing, including timing for the initiation of and reporting results ...

Deep Insights Advancing Impactful Medicines Company Overview | January 2025 © 2025 Scholar Rock, Inc. All rights reserved. Forward-Looking Statements Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock Holding Corporation and Scholar Rock, Inc. (collectively, "Scholar Rock"), including without limitation, Scholar Rock's expectations regarding its strategy, its product candidate selection and development timing, including timing for the initiation o ...

Dedicated to Dramatically Improving the Lives of Patients with SMA Q1 2025 Business Update May 14, 2025 © 2025 Scholar Rock, Inc. All rights reserved. Q1 Earnings Call | TO P I C | S P E A K E R | | --- | --- | | Scholar Rock Next Phase of Growth | David L. Hallal | | | Chief Executive Officer | | R&D Progress | Akshay Vaishnaw, M.D., Ph.D | | | President of R&D | | Commercial Readiness | Keith Woods | | | Chief Operating Officer | | Company Financials | Vikas Sinha | | | Chief Financial Officer | | Q&A Ses ...

Shares of Scholar Rock Holding (SRRK 14.77%) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly.Scholar Rock, a biopharma company, reported positive results from a phase 2 trial of its muscle-preserving weight-loss therapy.Significant resultsThe study evaluated Scholar Rock's apitegromab in combination with Eli Lilly's blockbuster weight-loss drug tirzepatide (sold as Mounjaro and Zepbound). The combo showed a significant reduction in lean mas ...

Scholar Rock SRRK revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss.Tirzepatide is an active ingredient in Eli Lilly And Co’s LLY widely used Mounjaro and Zepbound for diabetes and weight loss, respectively.The trial demonstrated that 30% of the total weight loss with tirzepatide alone was due to lean mass loss.Apitegromab therapy (10 mg/kg) with tripeptide preserved ...

Positive Ph2 EMBRAZE Trial Demonstrating Preservation of Lean Mass with Highly Selective Anti-Myostatin Inhibitor During Tirzepatide-Induced Weight Loss June 18, 2025 © 2025 Scholar Rock, Inc. All rights reserved. Today's Speakers David L. Hallal Chief Executive Officer Akshay Vaishnaw, M.D., Ph.D. President, Research & Development © 2025 Scholar Rock, Inc. All rights reserved. 2 Agenda | TOPIC | SPEAKER | | --- | --- | | Scholar Rock's Leading | David L. Hallal | | Anti-Myostatin Platform | Chief Executive ...

Scholar Rock Holding (SRRK) Update / Briefing June 18, 2025 08:00 AM ET Speaker0 Good morning, and welcome to ScholarRock's presentation of top line data from the Phase two EMPRAISE proof of concept trial. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. To ask a question, you may press star then 11 on your touch tone phone. To withdraw your question, please press then 11 again. This call is being recorded on Wednesday, 06/18/2025. I ...

Scholar Rock Holding (SRRK) FY 2025 Conference June 11, 2025 09:20 AM ET Speaker0 Joining us, I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and it's a pleasure to have, with us David Halal, the CEO of ScholarRock. So, David, to to start here, you recently took over as the CEO of ScholarRock after after serving as the Chairman of the Board of Directors since 2017, and you were previously the CEO of Alexion. Can you discuss your decision to step into this role, and your vision for the company, ...

Scholar Rock Holding (SRRK) 2025 Conference June 04, 2025 03:45 PM ET Speaker0 Fantastic. All right. Well, thank you. Good afternoon everyone. Welcome to the next session here at the Jefferies Healthcare Conference. I'm Michael Yee, a senior biotechnology analyst, and really happy to have a couple members of the ScholarRock management team with us. And importantly, this somewhat of a new team that got introduced over the last month. So I'd love perhaps, although David, you were chairman, an opportunity for ...

Scholar Rock Holding (SRRK) Q1 2025 Earnings Call May 14, 2025 08:15 AM ET Company Participants Rushmie Nofsinger - Vice President of Corporate Affairs & Investor RelationsDavid Hallal - CEO & ChairmanAkshay Vaishnaw - President, R&DKeith Woods - COOVikas Sinha - CFOMichael Yee - Managing DirectorDavid Nierengarten - Managing Director - Equity ResearchGary Nachman - Managing Director - Equity ResearchMalcolm Hoffman - Senior BioPharma Equity Research AssociateAndres Maldonado - Vice President Conference Cal ...